May 23, 2023, Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) trading session started at the price of $22.31, that was -1.62% drop from the session before. During the day, the shares moved up to $23.05 and dropped to $21.605 before settling in for the closing price of $22.26. A 52-week range for SNDX has been $13.82 – $29.86.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
When this article was written, the company’s average yearly earnings per share was at -628.70%. With a float of $57.43 million, this company’s outstanding shares have now reached $69.44 million.
In an organization with 107 employees, it is important to assess its efficiency.
Syndax Pharmaceuticals Inc. (SNDX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Syndax Pharmaceuticals Inc. stocks. The insider ownership of Syndax Pharmaceuticals Inc. is 0.30%, while institutional ownership is 90.20%. The most recent insider transaction that took place on May 09, was worth 1,131,478. In this transaction Director of this company sold 52,855 shares at a rate of $21.41, taking the stock ownership to the 17,836 shares. Before that another transaction happened on Apr 10, when Company’s Director sold 52,855 for $19.53, making the entire transaction worth $1,032,237. This insider now owns 17,836 shares in total.
Syndax Pharmaceuticals Inc. (SNDX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 3/30/2023, it has been observed that the corporation posted -$0.59 earnings per share (EPS) during the time that was better than consensus figure (set at -$0.6) by $0.01. This company achieved a return on equity of -34.10. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.83 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -628.70% per share during the next fiscal year.
Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Trading Performance Indicators
You can see what Syndax Pharmaceuticals Inc. (SNDX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 18.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.42, a number that is poised to hit -0.73 in the next quarter and is forecasted to reach -3.00 in one year’s time.
Technical Analysis of Syndax Pharmaceuticals Inc. (SNDX)
Let’s dig in a bit further. During the last 5-days, its volume was 1.03 million. That was better than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 72.51%. Additionally, its Average True Range was 0.95.
During the past 100 days, Syndax Pharmaceuticals Inc.’s (SNDX) raw stochastic average was set at 24.87%, which indicates a significant decrease from 65.55% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 43.02% in the past 14 days, which was higher than the 42.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.05, while its 200-day Moving Average is $23.44. However, in the short run, Syndax Pharmaceuticals Inc.’s stock first resistance to watch stands at $22.76. Second resistance stands at $23.63. The third major resistance level sits at $24.21. If the price goes on to break the first support level at $21.32, it is likely to go to the next support level at $20.74. Assuming the price breaks the second support level, the third support level stands at $19.88.
Syndax Pharmaceuticals Inc. (NASDAQ: SNDX) Key Stats
There are 68,821K outstanding shares of the company, which has a market capitalization of 1.48 billion. As of now, sales total 0 K while income totals -149,340 K. Its latest quarter income was 0 K while its last quarter net income were -41,130 K.
